AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

A multi-billion-dollar cash offer and a 60% premium are on the table as AbbVie nears its biggest buyout in seven years.

Diana Ross missing the target with her penalty. The goal breaking in half anyway. The nice red trouser suit Ross was wearing. Truly, the World Cup opening ceremony is the event that happens before the ...

It’s tough to avoid the current hype about the health benefits of injecting peptides. Although these substances – essentially, synthetic bits of protein in solution – have long made the rounds in the ...

Saphnelo (anifrolumab) is a medicine used to treat systemic lupus erythematosus (SLE). Lupus is a long-term autoimmune condition in which the immune system attacks the body’s healthy tissues. Saphnelo ...

April 29 (Reuters) - AbbVie (ABBV.N), opens new tab on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as ‌it ...

Gut bacteria aren’t just passive passengers—they can actively send proteins straight into our cells. Using microscopic injection systems, even harmless microbes can influence immune responses and ...

Wegovy is administered once weekly on the same day each week through subcutaneous injection into the thigh, abdomen, or upper arm, with sites rotated to prevent skin irritation. Proper injection ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. First, ...

The Outpost map is now available in Marathon, and you can finish the Introducing: Sekiguchi contract to gain access to the faction. Like all other liaison contracts, this one is slightly tricky to ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...